Comparison of pharmacogenetics-based warfarin dosing algorithms in Chinese Han population

Chinese Pharmaceutical Journal

Volumn 46, Issue 24, 2011, Pages 1929-1934

  Zhu, Jin ^a   Zhang, Wei ^a   Zhang, Wei Juan ^a   Wang, He Yao ^a   Wang, Chen ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CYP2C9; Pharmacogenetics; VKORC1; Warfrin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ACCURACY; ALGORITHM; ARTICLE; CHINESE; COMPARATIVE STUDY; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; POPULATION RESEARCH; PREDICTIVE VALUE; VENOUS THROMBOEMBOLISM;

EID: 84864959279     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. KURNIK D, LOEBSTEIN R, HALKIN H, et al. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal [J]. Pharmacogenomics, 2009, 10(12): 1955-1965.
2. TAN G M, WU E, LAM Y Y, et al. Role of warfarin pharmaco-genetic testing in clinical practice [J]. Pharmacogenomics, 2010, 11(3): 439-448.
3. LEE M T, CHEN C H, CHOU C H, et al. Genetic determinants of warfarin dosing in the Han-Chinese population [J]. Pharmacogenomics, 2009, 10(12): 1905-1913.
4. GAGE B F, LESKO L J. Pharmacogenetics of warfarin: regulatory, scientific, and clinic issues [J]. J Thromb Thrombolysis, 2008, 25(1): 45-51.
5. INTERNATIONAL WARFARIN PHARMACOGENETICS CONSORTIUM, KLEIN T E, ALTMAN R B, ERIKSSON N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data [J]. N Engl J Med, 2009, 360(8): 753-764.
6. MIAO L, YANG J, HUANG C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin; proposal for a new dosing regimen in Chinese patients [J]. Eur J Clin Pharmacol, 2007, 63(12): 1135-1141.
7. ANDERSON J L, HORNE B D, STEVENS S M, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J]. Circulation, 2007, 116(22: 2563-2570.
8. SCONCE E A, KHAN T I, WYNNE H A, et al. The impact of CYP2C9 and VK0RC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen [J]. Blood, 2005, 106(7): 2329-2333.
9. WADELIUS M, CHEN L Y, LINDH J D, et al. The largest prospective warfarin-treated cohort supports genetic forecasting [J]. Blood, 2009, 113(4): 784-792.
10. HUANG S W, CHEN H S, WANG X Q, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients [J]. Pharmacogenet Genomics, 2009, 19(3): 226-234.
11. ZHU Y, SHENNAN M, REYNOLDS K K, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639G > A) and CYP2C9 genotypes [J]. Clin Chem, 2007, 53(7): 1199, 1205.
12. YOU J H, WONG R S, WAYE M M, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients [J]. J Thromb Thrombolysis, 2011, 31 (1) : 113-118.
13. WANG T L, LI H L, TJONG W Y, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese [J]. Clin Chim Acta, 2008, 396(1-2): 76-79.
14. MAHAJAN P, MEYER K S, WALL G C, et al. Clinical applications of pharmacogenomics guided warfarin dosing [J]. Int J Clin Pharm, 2011, 33(1): 10-19.
15. YOU J H. Pharmacoeconomic evaluation of warfarin pharmacogenomics [J]. Expert Opin Pharmacother, 2011, 12(3): 435-441.
16. GANDARA E, WELLS P S. Will there be a role for genotyping in warfarin therapy [J]. Curr Opin Hematol, 2010, 17(5): 439-443.
17. LUBITZ S A, SCOTT S A, ROTHLAUF E B, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population [J]. J Thromb Haemost, 2010, 8(5): 1018-1026.
18. ROPER N, STROER B, BONA R, et al. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing [J]. J Mol Diagn, 2010, 12(3): 283-291.
19. SHIN J, CAO D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort [J]. Pharmacogenomics, 2011, 12(1): 125-134.
20. LUO X, XU K. A solid phase method for extracting DNA from whole blood [J]. Chin J Clin Lab Sci, 2004, 22(2): 123-125.
21. ZHU J, ZHANG W, LI Y, et al. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese [J]. Pharmacogenomics, 2010, 11(17): 113-119.
22. CHERN H D, UENG T H, FU Y P, et al. CYP2C9 polymor-phism and warfarin sensitivity in Taiwan Chinese [J]. Clin Chim Acta, 2006, 367(1-2): 108-113.
23. HARADA T, ARIYOSHI N, SHIMURA H, et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm [J]. Thromb Res, 2010, 126(3): 183-190.
24. LURIE Y, LOEBSTEIN R, KURNIK D, et al. Warfarin and vitamin K intake in the era of pharmacogenetics [J]. Br J Clin Pharmacol, 2010, 70(2): 164-170.